Pallab Saha
Technical Manager at Molbio Diagnostics Pvt. Ltd, IndiaPresentation Title:
Enhancing early screening for High Risk HPV (16, 18, 31 & 45) and Cervical Cancer: Truenat's prognostic impact in resource limited North East India internationally bordered with Myanmar, Nepal, Bhutan , Bangladesh and China
Abstract
Cervical cancer, the fourth most
common cancer in women, has an incidence rate of approximately 13.3 per
100,000, with 604,000 new cases annually. HPV RTPCR testing offers greater
sensitivity for detecting high risk strains than traditional Pap smears. Northeastern
India faces diagnostic access challenges, sharing border with regions like
Nepal, Bhutan, Myanmar, China, and Bangladesh, where HPV prevalence is 512%.
This study examines Truenat, a chip based, portable, real time micro PCR
system, as a cost effective, point of care solution for identifying high risk
HPV genotypes (16, 18, 31, 45) in resource limited settings.
DNA was isolated by cartridge
based extraction system within 17mins through microfluidics technique from
500ul of cervical swab samples. 6ul DNA combined with lyophilized master mix
after 30sec loaded on Truenat RTPCR disease specific chip. where 35mins results
were obtained through real-time graphical and CT based presentation of the
target and Internal positive control. End to end patient reporting including
extraction & RTPCR was achieved within 1hour per bay.
In the four year cohort study,
initiated in 2021, a total of 1,800 women underwent Truenat HPV-HR screening,
resulting in a 5.9% positivity rate for high risk HPV types. Of the
participants, 92% were aged 25 to 60. The positivity rates by age group were 8.5%
for those under 25, 6.7% for ages 25-40, 4.8% for ages 40-60, and 8.9% for
those over 60. Among positive cases, 75.7% were types 16/31 and 23.3% were
types 18/45, with one case of co-infection.
The Truenat HPV-HR screening offers a portable, cost
effective method to detect high risk HPV in women aged 25-60 in Northeast
India. This study underscores the urgent need for accessible cervical cancer
screening in underserved areas, promoting early detection and including genome
sequencing to underway for assessing comprehensive HPV prevalence across
demographics.
Biography
Dr. Pallab Saha holds a Ph.D. from Calcutta University, funded by University Grants Commission,India project and a Diploma in Chemical & Instrumental Process Control from Annamalai University. With over 25 years in in-vitro diagnostics, he specializes in Clinical Biochemistry, Immunology, and Hematology, having analyzed approximately 250,000 clinical samples across cancer, thyroid, anemia, diabetes, and CBC assessments. In the past seven years, Dr. Saha has focused on public health initiatives across India, Bangladesh, Nepal, Bhutan, and other SAARC countries, contributing significantly to Tuberculosis, Hepatitis, and Cervical Cancer elimination programs specifically in hard to reach, resource limited areas. He has played a pivotal role in the COVID-19 response as well, specifically in RTPCR point of care detection since the outset of the pandemic. Dr. Saha brings extensive expertise in quality management systems, excelling in internal, external, and intra-laboratory quality controls, with a strong focus on achieving laboratory service accreditation.
Organization Location
1309 Coffeen Avenue, STE 1200, Sheridan, Wyoming 82801, USA
Mail us at
Program Enquiry
gynecology@scientexconferences.com
General Queries
gynecology@scientexevents.com
Registration Enquiry
gynecology@scientexconferences.com
gynecology@scientexevents.com
Our Social Presence
Call us at
USA: : (+1) 323 723 3691